NASDAQ:CRDF
Cardiff Oncology Inc. Stock News
$3.63
-0.110 (-2.94%)
At Close: May 17, 2024
Cardiff Oncology Announces First Quarter 2021 Results and Recent Highlights
04:10pm, Thursday, 06'th May 2021
SAN DIEGO, May 6, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new t
Strength Seen in Cardiff Oncology (CRDF): Can Its 10.3% Jump Turn into More Strength?
04:31am, Thursday, 06'th May 2021
Cardiff Oncology (CRDF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near
Rising P/E: An Overlooked Way to Pick 5 Winning Stocks
06:46am, Thursday, 29'th Apr 2021
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Rising P/E: An Overlooked Strategy to Pick Winning Stocks
07:39am, Wednesday, 14'th Apr 2021
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Cardiff Oncology's Onvansertib Shows Durable Response, Progression-Free Survival In Colorectal Cancer Patients
10:18am, Monday, 12'th Apr 2021
Cardiff Oncology Inc (NASDAQ: CRDF) has announced data from its ongoing Phase 1b/2 trial evaluating onvansertib combined with standard-of-care therapy in second-line KRAS-mutated metastatic colore
SAN DIEGO, April 12, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new
SAN DIEGO, April 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new
Cardiff Oncology to Host Key Opinion Leader Webinar on Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer
08:30am, Thursday, 08'th Apr 2021
SAN DIEGO, April 8, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new t
7 Stocks That Could Double by Summer
02:29pm, Monday, 05'th Apr 2021
These seven stocks may be risky, but they also have the potential for big returns -- as all of them are stocks that could double by summer. The post 7 Stocks That Could Double by Summer appeared first
Insiders Buy Cardiff Oncology For Its Cash On Hand, Promising Trial Results
03:28pm, Thursday, 25'th Mar 2021
The Insurgent AI Innovation Model is a holistic machine learning system that has triggered a strong buy alert for Cardiff Oncology, ranking it in the top 6% of its investment universe.
Cardiff Oncology to Present at the Oppenheimer 31st Annual Healthcare Conference
08:30am, Thursday, 11'th Mar 2021
SAN DIEGO, March 11, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treat
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2021
04:30pm, Wednesday, 10'th Mar 2021
SAN DIEGO, March 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatm
Cardiff Oncology: Can They Succeed Where Others Have Failed?
04:07pm, Thursday, 25'th Feb 2021
Cardiff Oncology: Can They Succeed Where Others Have Failed?
Cardiff Oncology's Onvansertib Combo Associated With Two-Fold Increase Disease Control Rate In Prostate Cancer Study
11:11am, Thursday, 11'th Feb 2021
Cardiff Oncology Inc (NASDAQ: CRDF) has announced updated data from its Phase 2 trial evaluating the oral combination of onvansertib, Johnson & Johnson's (NYSE: JNJ) Zytiga (abiraterone), and
7 Healthy Medical Stocks to Buy
11:42am, Tuesday, 09'th Feb 2021
Some medical stocks gained momentum because of the pandemic, while others focus on high-reward challenges like cancer treatment. The post 7 Healthy Medical Stocks to Buy appeared first on InvestorPlac
